Innovation in India Series: An Analysis of Select Pharma Biotech Start-ups
Innovation is still in its nascent stage in the Indian Pharma sector but like the west it is being nurtured in the backyards of few innovator start-up companies. Unlike the west IPO is not the popular route of raising capital in India for innovator companies as the public perception, appreciation and understanding of the technology and innovation, value of intellectual property is very limited. However, there still exist a few entrepreneurs/ innovator companies who are “in the pursuit of happiness” managing funds through grants, angel investors and personal assets. Indian Pharma Companies and VC’s are willing to shop abroad but are sceptical about the efforts and science of home grown technologies. They need to realize that the outcome of research and clinical trial- success and failures are universal! Long term growth can only come from innovative patent protected products and in this report, we highlight some of the promising Indian innovator companies.
The companies, we have covered in detail, include
i) Bugworks, the 1st awardee of the CARB-X grant from Asia developing novel anti-infectives for serious drug resistant infections. The knowledge that there are “Bad Bugs, but No Drugs” has been there from more than two decades but efforts of fighting with new warfare has not been very successful worldwide. We elaborate on this urgent need and the potential of an innovative antibiotic for serious infections.
ii) Vitas Pharma also focuses on developing novel anti-infectives.
iii) Levim Biotech is focusing on microbial recombinant proteins/biosimilars API, synthetic peptide based therapeutics and proprietary drug delivery technologies.
iv) Saksin Lifesciences is focusing on proprietary bio better molecules.
v) Cellix Bio has churned out an impressive pipeline of patented NME’s that can be developed by the 505(2)(b) route targeting chronic diseases.
vi) Plasmagen is expected to start the manufacturing of safe and affordable therapeutic human plasma proteins.
vii) APAC Biotech has made a beginning in cell based immunotherapy/ personalised therapy for various cancer.
The companies, we have covered in detail, include
i) Bugworks, the 1st awardee of the CARB-X grant from Asia developing novel anti-infectives for serious drug resistant infections. The knowledge that there are “Bad Bugs, but No Drugs” has been there from more than two decades but efforts of fighting with new warfare has not been very successful worldwide. We elaborate on this urgent need and the potential of an innovative antibiotic for serious infections.
ii) Vitas Pharma also focuses on developing novel anti-infectives.
iii) Levim Biotech is focusing on microbial recombinant proteins/biosimilars API, synthetic peptide based therapeutics and proprietary drug delivery technologies.
iv) Saksin Lifesciences is focusing on proprietary bio better molecules.
v) Cellix Bio has churned out an impressive pipeline of patented NME’s that can be developed by the 505(2)(b) route targeting chronic diseases.
vi) Plasmagen is expected to start the manufacturing of safe and affordable therapeutic human plasma proteins.
vii) APAC Biotech has made a beginning in cell based immunotherapy/ personalised therapy for various cancer.
1. LIST OF TABLES
2. LIST OF FIGURES
3. EXECUTIVE SUMMARY
4. LEVIM BIOTECH
Executive Summary
Therapy Focus
Technology Platform
Services
Facility
Marketed Product – Recombinant Streptokinase
Pipeline – Biosimilars/biologics API
5. BUGWORKS
Executive Summary
Technology Platform
Focus- Serious Gram-Negative Infections
Pipeline
6. CELLIX BIO
Executive Summary
Technology Platform
Pipeline
Intellectual Property
7. PLASMAGEN BIOSCIENCES
Executive Summary
Focus on Unmet need and Untapped resource
Market Overview
Plasma Scenario- Challenges
Current Plasma Fractionation Yields
8. SAKSIN LIFE SCIENCES
Executive Summary
Technology Platform
Advantages of the novel Bio-Better for AMD
Business model
Market Overview
9. APAC BIOTECH
Executive Summary
Technology platform
Focus
10. VITAS PHARMA
Executive Summary
Technology Platform
Pipeline
Focus: Microbial – Multi-Drug Resistance
2. LIST OF FIGURES
3. EXECUTIVE SUMMARY
4. LEVIM BIOTECH
Executive Summary
Therapy Focus
Technology Platform
Services
Facility
Marketed Product – Recombinant Streptokinase
Pipeline – Biosimilars/biologics API
5. BUGWORKS
Executive Summary
Technology Platform
Focus- Serious Gram-Negative Infections
Pipeline
6. CELLIX BIO
Executive Summary
Technology Platform
Pipeline
Intellectual Property
7. PLASMAGEN BIOSCIENCES
Executive Summary
Focus on Unmet need and Untapped resource
Market Overview
Plasma Scenario- Challenges
Current Plasma Fractionation Yields
8. SAKSIN LIFE SCIENCES
Executive Summary
Technology Platform
Advantages of the novel Bio-Better for AMD
Business model
Market Overview
9. APAC BIOTECH
Executive Summary
Technology platform
Focus
10. VITAS PHARMA
Executive Summary
Technology Platform
Pipeline
Focus: Microbial – Multi-Drug Resistance
